GlobeNewswire by notified

EXEL Industries: 2022–2023 revenue up 12.0%

Share
2022–2023 revenue up 12.0%

Group revenue crosses the €1 billion threshold driven by strong growth in Agricultural Spraying


Q4 sales
(July 2023–
September 2023)

2021–20222022–2023Change
(reported)
Change
(LFL*)
Reported Reported €m % €m %
AGRICULTURAL SPRAYING

122.5 133.2 +10.7 +8.7% +18.0 +14.7%
SUGAR BEET HARVESTERS

85.3 70.7 (14.5) (17.0)% (14.1) (16.5)%
LEISURE



28.1 23.7 (4.4) (15.6)% (6.0) (21.4)%
INDUSTRY



61.7 73.6 +11.9 +19.3% +14.5 +23.5%
EXEL Industries Group 297.5 301.2 +3.7 +1.2% +12.4 +4.2%


12 months sales
(October 2022–
September 2023)

2021–20222022–2023Change
(reported)
Change
(LFL*)
Reported Reported €m % €m %
AGRICULTURAL SPRAYING 442.3 525.2 +82.9 +18.7% +85.3 +19.3%
SUGAR BEET HARVESTERS

146.3 158.6 +12.3 +8.4% +16.0 +10.9%
LEISURE



138.9 143.6 +4.7 +3.4% (1.2) (0.9)%
INDUSTRY

249.5 266.8 +17.3 +6.9% +20.1 +8.1%
EXEL Industries Group 977.0 1,094.3 +117.3 +12.0% +120.2 +12.3%

* Like-for-like (LFL) = at constant foreign exchange rates and scope

Sales per activity
Fourth quarter 2022–2023

EXEL Industries posted revenue of €301.2 million for the fourth quarter of fiscal 2022–2023, up 1.2%. However, growth at constant consolidation scope and foreign exchange rates was 4.2%, the difference being due to an adverse currency effect and a limited scope effect arising from the consolidation of the Devaux group: the early June 2023 acquisition of Devaux led to the consolidation of a €2.0 million contribution to fourth quarter revenue.

  • AGRICULTURAL SPRAYING UP 8.7%

The fourth quarter of 2021–2022 was a catch-up quarter, following two consecutive quarters in which supply shortages penalized production and, consequently, deliveries. In the fourth quarter of 2022–2023, Western Europe (France, Germany), North America and Australia drove growth in machine sales volumes.

  • SUGAR BEET HARVESTERS DOWN 17.0%

After a first half marked by exceptional deliveries in Eastern Europe, sales volumes returned to a more typical seasonal pattern this quarter. Sugar prices, which have remained at all-time highs throughout 2023, supported demand in Europe.

  • LEISURE DOWN 15.6%

Hit by adverse weather conditions, Garden sales were down in the fourth quarter, in a declining market for the second consecutive year. Despite a slight upturn in September, dealers preferred to run down existing inventories rather than place new orders, thereby impacting volumes. The integration of Devaux is progressing according to plan.
Deliveries in the Nautical business improved in the fourth quarter, making up for the shortfall in the third quarter.

  • INDUSTRY UP 19.3%

Industrial spraying revenue increased significantly thanks to the completion and invoicing of a large number of projects. Growth was particularly strong in Western Europe (Germany) and Asia (China).

Full-year
2022–2023 sales

Full-year 2022–2023 sales amounted to €1.1 billion, up 12.0%. Growth at constant foreign exchange rates and scope was 12.3%. This performance was underpinned by price increases during the year and strong volumes in the agricultural equipment and industrial segments.

The scope effect represents €8.1 million in revenue over the 2022–2023 fiscal year, following the acquisitions of G.F. in February 2022 and Devaux in June 2023.

  • AGRICULTURAL SPRAYING UP 18.7%

Business was strong throughout the year, after a 2021–2022 fiscal year marked by production difficulties arising from part and component shortages. Strong demand and production delays in the previous year at all of our European and American plants led to a change in the seasonal pattern of our business: deliveries were strong in the first half for machines that had not been delivered in the previous period. Price increases incorporated into the order book over several months in response to inflation also contributed to revenue growth.

  • SUGAR BEET HARVESTING UP 8.4%

Sales of new machines benefited from record sugar prices since spring, the early year delivery of machines from Eastern Europe and the release of the new Terra Dos 5 harvester. However, the business continued to suffer from supply disruptions. Finally, inventory clearance of used machines is progressing steadily.

  • LEISURE UP 3.4%

After last year’s upturn, the sharp decline in the Western European market (UK, France, Italy) continued during the fiscal year, without affecting market share. Price increases made early in the fiscal year helped to mitigate inflation but failed to offset lower sales volumes.
The Nautical business was broadly stable compared with the previous year, pending the launch of new models scheduled for 2024. The sales, marketing and manufacturing teams have now been fully ramped up.

  • INDUSTRY UP 6.9%

Underlying markets (automotive, furniture and industry), favorable to spare parts sales, showed encouraging trends this year, mainly in Asia and Europe, and to a lesser extent in North America. Furthermore, the construction of electric car production sites in Asia boosted sales for both high viscosity products from the Sames iNTEC factory, acquired in 2020, and electrostatic spraying solutions.
Throughout the year, the Technical Hoses activity was affected by slower B2B demand (construction, agribusiness), as well as a decline in its Garden business.

Yves Belegaud, Chief Executive Officer of the EXEL Industries Group:

“For the first time, the EXEL Industries Group has exceeded the 1-billion-euro revenue mark. Once again, this year, the Group’s brands were able to compensate for higher production costs in an inflationary environment, thanks to a disciplined approach to adjusting their selling prices, regardless of the end market, and a good industrial performance. Increased sales volumes in the Agricultural equipment and Industrial spraying activities made a significant contribution to growth in billings over the fiscal year.”

Upcoming events

  • December 21, 2023, before market opening: 2022–2023 full-year results & SFAF presentation
  • January 25, 2024, before market opening: Q1 2023–2024 sales
  • February 6, 2024: Annual General Meeting of Shareholders

About EXEL Industries

EXEL Industries is a French family-owned group that designs, manufactures, and markets capital equipment and provides associated services that enable its customers to improve efficiency and productivity or enhance their well-being while achieving their CSR objectives.
Driven by an innovation strategy for over 70 years, EXEL Industries has based its development on innovative ideas designed to offer customers unique, efficient, competitive, and user-friendly products.
Since its inception, the Group has recorded significant growth in each of its markets through both organic growth and corporate acquisitions, underpinned by a stable shareholder base guided by a long-term development strategy. EXEL Industries employs approximately 3,879 permanent employees spread across 27 countries and five continents. The Group posted FY 2022–2023 sales of €1.1 billion.
Euronext Paris, SRD Long only – compartment B (Mid Cap) EnterNext© PEA-PME 150 index (symbol: EXE/ISIN FR0004527638)

Press release available onsite www.exel-industries.com

Yves BELEGAUD
Chief Executive Officer
Thomas GERMAIN
Group Chief Financial Officer / Investor relations
direction.communication@exel-industries.com

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

798 Launches Folk Culture Sector of Square Art Festival, 110,000+ Visitors Reached During the Chinese New Year Vacation24.2.2024 03:00:00 CET | Press release

BEIJING, Feb. 24, 2024 (GLOBE NEWSWIRE) -- 798 Art District announces today that the Folk Culture Sector of the 798 Square Art Festival will launch on February 24, 2024, at the CONCERTED SQUARE of 798 Art District in Beijing. This sector aims to bridge contemporary art with urban and rural folk culture. Visiting 798 during the Lantern Festival, you can experience the power of contemporary art intertwined with traditional folk customs and enjoy the familiar yet strange world of Chinese local culture. Event Poster February 24 is the Lantern Festival in China, and it marks the end of the Chinese New Year festivities. The New Year vacation in 798 was full of lively atmosphere. Throughout the Spring Festival, 15 exhibitions were ongoing in 798, including the Joy Art Museum's "Joy in the Year of the Dragon", IOMA Art Center's "Dragon Roaming the World and Prospering", MOCUBE's "Upon Arrival of Dragon", and Le Rime Gallery's "Jia Chen Mountain Chronicle". Based on statistics, there were over

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®24.2.2024 02:15:00 CET | Press release

SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar approval under the strategic partnership between Alvotech and Teva in the U.S. market SIMLANDI will qualify for interchangeable exclusivity in the U.S. for some concentration strengths Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SIMLANDI (adalimumab-ryvk) injection, as an interchangeable biosimilar to Humira, for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adul Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SIMLANDI (adalimumab-ryvk) injection, as an interchan

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons23.2.2024 23:50:47 CET | Press release

Company Announcement COPENHAGEN, Denmark; February 23, 2024 –Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company’s managerial employees and their closely associated persons. Please find below a statement of such trading in shares issued by Genmab A/S 1.Details of the person discharging managerial responsibilities / person closely associateda)NameJan G. J. van de Winkel2.Reason for the notificationa)Position/statusPresident & Chief Executive Officerb)Initial notification/AmendmentInitial notification3.Details of the issuer, emission allowance market participant, auction platform,

Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab23.2.2024 23:35:31 CET | Press release

Company Announcement COPENHAGEN, Denmark; February 23, 2024 –Genmab A/S (Nasdaq: GMAB) announced today that the board decided to grant 418,646 restricted stock units to members of management and employees of the company as well as the company's subsidiaries and 316,899 warrants to employees of the company and the company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. The vesting of the restricted stock units granted to the members of executive management will, with the exception of deferred annual cash bonus, be subject to forward looking performance criteria and consequently represent the maximum opportunity available if the performance targets have been significantly exceeded. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 2,013. The restricted stock units will vest on the first ban

Karate Combat 46 to enhance Dubai’s standing as a leading sports tourism destination23.2.2024 20:00:38 CET | Press release

KC46 will be held on Saturday 20 April First professional sports league gamified by a blockchain access token DUBAI, United Arab Emirates, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Karate Combat, the world’s premier full-contact professional striking league, has partnered with Dubai Department of Economy and Tourism (DET) and Dubai Sports Council (DSC) to bring Karate Combat 46 (KC46) to the emirate this spring. Expected to be the league’s biggest event to date, KC46 is collaborating with TOKEN2049 for a Saturday 20 April event. As part of the collaboration KC46 will be part of the official programme of TOKEN2049 Week Dubai, giving conference attendees the opportunity to witness one of the world’s most innovative sports leagues through special tickets and the opportunity to meet event ambassadors at the conference. KC46 will be announced by UFC Hall of Famers Georges St-Pierre (GSP) and Bas Rutten, alongside Mike Majlak, author and co-host of the Impaulsive podcast. Karate Combat is the first

HiddenA line styled icon from Orion Icon Library.Eye